BUZZ-Organon rises after agreeing to sell postpartum bleeding device to Laborie for up to $465 mln** Shares of healthcare firm Organon OGN.N rise 2% to $6.85 premarket
** Co says it will sell its JADA System, a device used to treat postpartum bleeding, to Laborie Medical Technologies for up to $465 million
** Deal includes $440 mln upfront, $25 mln tied to 2026 sales targets – OGN
** OGN says ~100 of it's employees will move to Laborie as part of the agreement
** The JADA System, which OGN acquired in 2021, is used to manage postpartum hemorrhage, a serious complication after childbirth - OGN
** The transaction is expected to close in the first quarter of 2026, pending regulatory approvals, co says
** Up to last close, stock down ~55% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.